HSD3B7 as a prognostic-related biomarker predicts poor prognostic in ccRCC [post]

Zhiya Hu, Jiawu Wang, Yongxin Fu, Yisen Li, Qing Jiang
2022 unpublished
Backgrounds:Clear cell renal cell carcinoma (ccRCC) is a form of renal tumor with poor prognosis and insensitive to radiotherapy and chemotherapy. HSD3B7 is highly expressed in a variety of malignant tumors and is associated with poor prognosis. However, the role of HSD3B7 in clear cell renal cell carcinoma (ccRCC) is unclear. The purpose of this study is to determine the role of HSD3B7 in ccRCC by integrated bioinformatics analysis. Methods: The whole transcriptome data were downloaded from
more » ... Cancer Genome Atlas (TCGA) database. The expression and methylation data of HSD3B7 mRNA were obtained from TIMER, UALCAN and MethSurv databases. Linkedomics database is used to study the functional pathway of the genes co-expressed with HSD3B7. The TIMER and TISIDB databases were used to analyze the correlation between HSD3B7 and tumor infiltrating immune cells and immune modulators. The expression of HSD3B7 in different tumor cell lines and its relationship with drug response were analyzed by RNAactDrug and CCLE database. Results:The expression of HSD3B7 was significantly up-regulated in most cancer types. The mRNA and protein expression levels of HSD3B7 were significantly higher in normal tissues compared with ccRCC tissues. Kaplan-Meier survival curve showed that high HSD3B7 expression level predicted poor OS and PFS. The degree of DNA methylation of HSD3B7 in ccRCC was significantly lower than that in normal tissues. The pathway function enrichment analysis of HSD3B7 co-expressed genes suggested that HSD3B7 co-expressed genes were mainly involved in immune-related pathways. At the same time, the expression of HSD3B7 was also strongly correlated with immune infiltration level, immune regulators and chemokines. More importantly, the results of drug sensitivity suggested that the expression of HSD3B7 was closely related to the mechanism of many common renal cell carcinoma related drugs. Therefore, HSD3B7 can be a potential prognostic and prognostic biomarker and therapeutic target of ccRCC. Conclusions:The results suggested that HSD3B7 may be a potential prognostic biomarker and a new therapeutic target for ccRCC.
doi:10.21203/rs.3.rs-2138170/v1 fatcat:5sxitfbrwvg6tio7vtqr7pnhbm